VolitionRx Limited's Triage Test Results Validated in Prospective Trial

NAMUR, Belgium, Feb. 24, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) has presented data at the World Congress of GI Endoscopy (ENDO) 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.Q^TM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

"This is a key clinical milestone in the launch of our Nu.Q^TM Triage product. This validation study, in a second population of 1,961 subjects, greatly assists us with sales and marketing efforts in the EU and Asia," said Louise Day, Chief Marketing and Communications Officer at Volition.

The lead author of the study, Dr. Marielle Herzog, commented, "This data confirms the role that the Nu.Q^TM Triage test can play in accelerating the diagnosis of colorectal cancer."

The full data can be found at http://volitionrx.com/news/presentations

About Nu.Q^TM Colorectal Cancer Screening Triage Test

There is currently a significant strain on colonoscopy capacity which can lead to longer waiting times in European healthcare systems due to the expansion of colorectal cancer screening programs. Therefore, there is a pressing need to prioritise the colonoscopy referrals for those at high risk. Volitions aims to meet this need with its new Nu.Q^TM  Colorectal Cancer Screening Triage Test.

Having received a CE mark for the Nu.Q^TM Colorectal Cancer Screening Triage Test in December 2016, Volition plans to launch the test for the European Union screening population. 

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Austin, TX  and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/company/volitionrx

Facebook: https://www.facebook.com/VolitionRx/

YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q^TM and HyperGenomics® and and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

SOURCE VolitionRx Ltd